Mastering tissue specific RNA delivery for efficient cancer immunotherapy
We are dedicated to developing tissue specific RNA delivery for efficient cancer immunotherapy
RNA therapeutics have come to stay
mRNA helps produce therapeutics on site, without the need to manufacture these in industrial factories.
Immune system allows the activation of defense mechanism that has already been built into our body, without the need for intervening with foreign and toxic compounds.
Vectiopep is focusing on activation of the patient’s innate immune system to fight cancer. We achieve this by selective transport of mRNA into the immune cells in the patients’ body. Because Vectiopep has developed selective RNA delivery into immune tissues, we believe it can be used to treat cancer. Our innovation is based on the unique chemical composition of Vectiopep that utilizes specific cell penetrating peptides (CPP), enabling potent and selective RNA delivery.
Nucleic acid biomolecules – DNA and RNA – are integral part in each and every cell in our body and they control crucial aspects of our functioning. By administering specific nucleic acids, we could theoretically treat a number of diseases in the patients. However, since nucleic acids are large and unstable molecules, it is not possible to just inject these and we need an additional tool – nucleic acid delivery system. Such systems pack nucleic acid into nanoparticles, protect it from degradation, and transport it into the patients’ cells.
We believe that our technology, when combined with recent advancements with mRNA therapeutics, will be transformative in the future oncology field, offering unprecedented cancer treatment.
Our Expert Team
Having complementary backgrounds in chemistry, cell biology and animal models, we have over 10 years developed nucleic acid delivery technologies.
Kaido Kurrikoff, Ph.D.
Co-Founder & CEO
Piret Arukuusk, Ph.D.
Co-Founder & CTO